Upcoming Webinar: "What is the CONQUER Registry and what do patients need to know?"
|
|
Want to learn more about CONQUER (COllaborative, National QUality and Efficacy Registry), and why it's important to patients with scleroderma? Join us for our upcoming webinar, where Dr. Tracy Frech from the University of Utah and Dr. Shervin Assassi from the University of Texas, will explain what this data registry is, how to enroll and the benefits of participation.
Moderated by SRF Board Chair, Luke Evnin, PhD, this live webinar will take place on Tuesday, April 20th at 12:00PM CST/10:00AM PST. Check the SRF's social media accounts soon for more information and registration. Or contact Gloria Blecha, Director of Community Engagement, at gloria@sclerodermaresearch.org to be added to the invitation list.
|
|
What does AI have to do with Scleroderma?
|
|
Did you know that artificial intelligence (AI) could help improve scleroderma treatments? SRF-funded investigator Dr. Michael Whitfield has been working for many years to develop a classifier via an artificial intelligence algorithm for patients with scleroderma based on gene expression data.
The goal is to predict how individual patients might respond to a given treatment. Because certain scleroderma treatments can be risky, or have serious side effects, it would be hugely advantageous for patients to understand upfront whether they are likely to respond to a potential treatment.
|
|
Kheesa's journey with scleroderma
|
|
Kheesa’s symptoms started in 2005, but she wasn't diagnosed with scleroderma for two years, until after the birth of her first child.
Read more about her motivation for fighting scleroderma and why research is important to her.
|
|
New treatment for systemic sclerosis-related ILD available
|
|
The FDA has just approved Genentech’s Actemra for treatment systemic sclerosis-related interstitial lung disease (SSc-ILD). “We are honored to offer the very first FDA-approved biologic treatment option to people living with systemic sclerosis-associated interstitial lung disease,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development at Genentech. The SRF is excited that patients will have another option for treating SSc-ILD.
|
|
Global Patient Partnership Summit with Boehringer Ingelheim
|
|
Earlier this month, Boehringer Ingelheim (BI) hosted a virtual Two-Day Global Patient Partnership Summit that brought together hundreds of patients, patient organizations and BI representatives from all over the world. The SRF's Executive Director, Joanne Gold, and Director of Community Engagement, Gloria Blecha, were proud to be invited participants and contribute their insights and while also learning from other patient-focused organizations from around the world.
Participants collaborated to co-create solutions that will provide value to patients in four major health areas: 1) access to care and information, 2) raising awareness, 3) digital health and learnings from Covid-19, and 4) collaboration and innovation. By reviewing the outcomes and steps to take the identified solutions forward, the hope is to transform health for all patients.
|
|
The SRF earns 2021 Platinum Seal of Transparency from Guidestar
|
|
We're honored to have recently received the 2021 Platinum Seal of Transparency from Guidestar. This means our strategy, metrics, and achievements—what allows us to keep research at the center of all we do—are all available for anyone to view.
|
|
A 33-Year-Old Tradition honoring Kathryn Daub Hinman
|
|
As a young boy growing up, David Hinman remembers how his mother, Kathryn Daub Hinman, was always cold–something that was originally attributed to her having poor circulation. But years later in the 1970’s, she was diagnosed with scleroderma. David recalls how at the time “very little was known about the disease with hardly any research going on.” Sadly, Kathryn died in 1984 at age 73 from complications of the disease.
Not long afterwards, David read an article in the Wall Street Journal about Sharon Monsky and how she founded the Scleroderma Research Foundation with the mission to find a cure. “She was an MBA, like myself,” says David. “She was approaching the scleroderma problem like a business women, with the goal of putting the foundation out of business, when research found a cure.”
|
|
Sharon’s laser-focus resonated with David, so in November 1987 he began sending letters to friends and family to request donations to support the SRF in honor of his mother. More than 30 years later, he continues to make scleroderma research a priority by sending out his annual mailing and has raised over $15,000 to date. It’s a tradition that means a lot to David: “While addressing and stuffing envelopes each November, I think about and reflect on my Mother’s life and contemplate how much I miss her.”
We're grateful to David and all those who have helped him remember and honor Kathryn with their annual gifts. Thanks to their continued support, the SRF remains singularly focused on funding the most promising research so that one day there will be a cure.
Do you have a story about how you made a difference for a cure? We'd love to hear from you!
|
|
Make sure you're getting the emails you want from us!
|
|
We've introduced a new way for you to select what kind of information you want to receive from us: events & activities, news & updates, or patient information (or all!).
|
|
P.S. Make sure to add info@srfcure.org to your safe senders list, so that you never lose an update to your junk mail.
|
|
|
|
|
|
|